Eisai Asks Court To Set Deadline For DEA Scheduling Of Its Epilepsy Drug Fycompa
This article was originally published in The Pink Sheet Daily
Eisai says DEA’s scheduling delay – 10 months after FDA approval and seven months after HHS submitted a scheduling recommendation – is “unreasonable and egregious.” Court filing follows citizen petition to FDA.
You may also be interested in...
Eisai citizen petition requests Belviq and Fycompa approval dates coincide with final DEA scheduling; Pozen advocates exclusivity for new combinations of previously approved molecules.
Eisai’s Fycompa becomes only the second drug with a new mechanism of action approved by FDA for epilepsy in the last decade.
The agency's "Bad Ad" program issued a warning letter that claims the promotion for CooperSurgical's copper-containing intrauterine contraceptive lacked any safety information.